Subcutaneous Calcitonin in Acute Herpes Zoster

Recruiting now · Phase 3

Conditions studied: Calcitonin, Subcutaneous, Acute Herpes Zoster

In brief

This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.

Key facts

Study ID

NCT07655804

Run by

Tanta University

People needed

168

Starts

2026-07-01

Expected to finish

2027-10-01

Last updated by the study team

2026-07-06

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• patients aged ≥ 50 years, with acute herpes zoster infection (rash duration < 7 days) and moderate to severe pain.

You may not qualify if…

• Coagulation abnormalities
• Pre-existing other pain syndrome or psychological disorders.
• Severe hepatic, cardiovascular, or renal disorders.
• Allergy to calcitonin.

Where it is running

• Tanta University Hospitals — Tanta, Gharbia Governorate, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.